5/29
04:12 pm
rna
Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress [Yahoo! Finance]
Low
Report
Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress [Yahoo! Finance]
5/29
04:05 pm
rna
Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress
Low
Report
Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress
5/29
08:49 am
rna
2 Potentially High-Reward Growth Stocks to Buy Right Now [Yahoo! Finance]
Medium
Report
2 Potentially High-Reward Growth Stocks to Buy Right Now [Yahoo! Finance]
5/21
04:05 pm
rna
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/15
09:13 am
rna
Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors [Yahoo! Finance]
Low
Report
Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors [Yahoo! Finance]
5/15
09:00 am
rna
Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
Low
Report
Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
5/10
11:25 am
rna
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $33.00 price target on the stock.
Low
Report
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $33.00 price target on the stock.
5/10
08:39 am
rna
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock.
Medium
Report
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock.
5/9
04:07 pm
rna
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights [Yahoo! Finance]
Medium
Report
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights [Yahoo! Finance]
5/9
04:05 pm
rna
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
Medium
Report
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
5/8
04:12 pm
rna
Avidity Biosciences to Participate in Upcoming Investor Conference [Yahoo! Finance]
Medium
Report
Avidity Biosciences to Participate in Upcoming Investor Conference [Yahoo! Finance]
5/8
04:05 pm
rna
Avidity Biosciences to Participate in Upcoming Investor Conference
Low
Report
Avidity Biosciences to Participate in Upcoming Investor Conference
5/8
06:12 am
rna
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1 [Yahoo! Finance]
Low
Report
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1 [Yahoo! Finance]
5/8
06:00 am
rna
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1
Low
Report
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1
5/3
07:43 am
rna
Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $40.00 price target on the stock.
Low
Report
Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $40.00 price target on the stock.
4/25
09:22 am
rna
Artisan International Small-Mid Fund Q1 2024 Earnings Preview [Seeking Alpha]
Medium
Report
Artisan International Small-Mid Fund Q1 2024 Earnings Preview [Seeking Alpha]
4/25
08:30 am
rna
Strategies for Global Clinical Trials: Clinical Research Without Borders, Upcoming Webinar Hosted by Xtalks
Medium
Report
Strategies for Global Clinical Trials: Clinical Research Without Borders, Upcoming Webinar Hosted by Xtalks
4/22
04:05 pm
rna
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/18
05:01 pm
rna
FYBR, BCRX and SABR are among after hour movers [Seeking Alpha]
Low
Report
FYBR, BCRX and SABR are among after hour movers [Seeking Alpha]
4/11
08:06 am
rna
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock.
Low
Report
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock.
3/27
09:00 am
rna
Avidity Biosciences to Participate in Upcoming Investor Conferences
Low
Report
Avidity Biosciences to Participate in Upcoming Investor Conferences
3/21
04:05 pm
rna
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/14
08:30 am
rna
Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $60.00 price target on the stock.
Medium
Report
Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $60.00 price target on the stock.
3/5
01:58 pm
rna
Avidity Biosciences: Targeting A First Ever Approval In DM1 With Improving Data [Seeking Alpha]
Low
Report
Avidity Biosciences: Targeting A First Ever Approval In DM1 With Improving Data [Seeking Alpha]
3/4
07:17 am
rna
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial [Yahoo! Finance]
Medium
Report
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial [Yahoo! Finance]